Tuesday, 20 Mar 2018

You are here

NLRP3 Activation in Still's Disease

Adult-onset Still disease (AOSD) is usually regarded as an autoinflammatory disease, largely because of its symptomatology and responsiveness to IL-1 inhibition.  Thus while it is assumed that aberrant NLRP3 inflammasome activity underlies active AOSD, the connection between NLRP3 AOSD has yet to be solidfied.

Hseih et al have studied mRNA expression of NLRP3 inflammasome signaling using quantitative-PCR (qPCR) on peripheral blood mononuclear cells (PBMC) from 34 patients with AOSD and 14 healthy subjects. These results were either augmented with a NLRP3 activator [imiquimod (IMQ)] or inhibitor.

AOSD patients demonstrated significantly higher mRNA levels of NLRP3 signaling compared with controls. Moreover, NLRP3 expression was positively correlated with AOSD disease activity

IMQ (a TLR7 ligand and activator) stimulated higher expression of NLRP3, caspase-1 and IL-18.  These were decreased after treatment with NLRP3 inhibitor in patients with AOSD.

Increased expression of NLRP3 inflammasome and its correlation with disease activity in AOSD suggest its involvement in disease pathogenesis of AOSD.  Currently the inducers of NLRP3 activity in AOSD are unknown and would make for an ideal treatment target in the future.

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Using Synovial Tissue Biopsies to Develop Precision Medicine for Rheumatoid Arthritis

Researchers at Northwestern University have used ultrasound-guided tissue biopsy from the joints to analyze the genes of tissue macrophages with the hope that transcriptional profiling of synovial macrophages may be correlated with clinical parameters or drug responsiveness in rheumatoid arthritis (RA) patients.(Citation source: 

IL-18 Binding Protein Effective in Adult-Onset Still's Disease

Gabay and colleagues have reported the results of a novel new recombinant human IL-18 binding protein, tadekinig alfa, demonstrating its effectiveness in an open-label dose escalating study in patients with adult-onset Still's disease (AOSD).

NHANES Survey Shows OA Rising and RA Declining

An analysis of 43,706 adults from the 1999-2014 National Health and Nutrition Examination Surveys (NHANES) demonstrated temporal trends in the prevalence of arthritis, including a rise in osteoarthritis (OA) from 6.6% to 14.3%, while the prevalence of rheumatoid arthritis (RA) decreased from 5.9% to 3.8% in the USA, (Citation source https://buff.ly/2o6fhkW

DMARDs Lower Dementia Risk in Rheumatoid Arthritis

UK researchers have analyzed rheumatoid arthritis (RA) patients from the UK Clinical Practice Research Database and shown that chronic conventional DMARD (cDMARD) use was associated with 40% lower risk of dementia (nearly 50% with methotrexate use).

Abatacept Shows Promise for RA-ILD

Abatacept (Orencia) may be a useful treatment option for patients with rheumatoid arthritis (RA) who develop interstitial lung disease (ILD), a Spanish study suggested.